In July 2021, the Executive Committee of the Stop TB Partnership approved US$6.14 million for Wave 9 funding to be awarded to 11 projects, in 8 countries, focusing on innovative approaches to address drug resistant tuberculosis (DR-TB) with support from the United States Agency for International Development (USAID) and Global Affairs Canada
UZT was among recipients of this grant that will support scale-up of newer and shorter all-oral regimens for Drug resistant TB (DR-TB), through introduction of Xpert® MTB/XDR assay for detection of second-line drug resistance
For UZT, the TB Reach support will be for 2 years.
- Project Title: Optimizing SHORRT in Zimbabwe
- Project Goal: To treat all people with DR-TB
- Objectives
- To provide DST for FQ to at least 90% of patients detected with MDR/RR-TB
- To enroll at least 183 (100%) detected DR-TB patients on treatment
- To enroll at least 165 (90%) DR-TB patients on an all oral regimen
- To ensure a treatment success rate of at least 80% among DR-TB patients initiating treatment
Project Setting
The project will be implemented in Bulawayo, Midlands and Matabeleland South provinces, which contribute two thirds of national case load for DR-TB.
In 2023, with TB REACH support: